ID   Ej138
AC   CVCL_2443
SY   EJ138; EJ 138; MGH-U1; MGHU1; MGH-UI; MGH-U1 (EJ); EJ
DR   BTO; BTO:0003553
DR   CLO; CLO_0002905
DR   CLO; CLO_0002906
DR   CLDB; cl1152
DR   CLDB; cl1154
DR   BioSample; SAMN03151939
DR   BioSample; SAMN03151949
DR   cancercelllines; CVCL_2443
DR   ChEMBL-Cells; CHEMBL3307583
DR   ChEMBL-Targets; CHEMBL614292
DR   Cosmic; 760480
DR   Cosmic; 925828
DR   Cosmic; 1093986
DR   Cosmic; 1927289
DR   ECACC; 85061108
DR   GEO; GSM827443
DR   GEO; GSM1374473
DR   NCBI_Iran; C429
DR   Progenetix; CVCL_2443
DR   PubChem_Cell_line; CVCL_2443
DR   Wikidata; Q54832176
RX   PubMed=651066;
RX   PubMed=663932;
RX   PubMed=864752;
RX   PubMed=870558;
RX   PubMed=2903891;
RX   PubMed=3708594;
RX   PubMed=4027986;
RX   PubMed=6244232;
RX   PubMed=6823318;
RX   PubMed=6826254;
RX   PubMed=7185004;
RX   PubMed=11416159;
RX   PubMed=20143388;
RX   PubMed=20215515;
RX   PubMed=23401075;
RX   PubMed=25336970;
CC   Problematic cell line: Contaminated. Shown to be a T24 derivative (PubMed=3708594; PubMed=6823318; PubMed=20143388).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00080.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00195.
CC   Population: Caucasian; Swedish.
CC   Doubling time: 20 hours (PubMed=3708594).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by ESTs sequencing.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): PubMed=11416159
ST   Amelogenin: X
ST   D18S51: 16,18
ST   D21S11: 29
ST   D8S1179: 14
ST   FGA: 22
ST   TH01: 6
ST   vWA: 17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0554 ! T24
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
RX   PubMed=651066; DOI=10.5980/jpnjurol1928.69.1_40;
RA   Kato T., Ishikawa K., Nemoto R.;
RT   "Morphologic characterization of two established cell lines, T24 and
RT   MGH-U1, derived from human bladder carcinoma.";
RL   Nihon Hinyokika Gakkai Zasshi 69:40-46(1978).
RX   PubMed=663932; DOI=10.1620/tjem.124.33;
RA   Kato T., Ishikawa K., Nemoto R., Senoo A., Amano Y.;
RT   "Morphological characterization of two established cell lines, T24 and
RT   MGH-U1, derived from human urinary bladder carcinoma.";
RL   Tohoku J. Exp. Med. 124:339-349(1978).
RX   PubMed=864752; DOI=10.1093/jnci/58.6.1743;
RA   Marshall C.J., Franks L.M., Carbonell A.W.;
RT   "Markers of neoplastic transformation in epithelial cell lines derived
RT   from human carcinomas.";
RL   J. Natl. Cancer Inst. 58:1743-1751(1977).
RX   PubMed=870558; DOI=10.1177/25.4.870558;
RA   Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.;
RT   "Alkaline phosphatase activity in human bladder tumor cell lines.";
RL   J. Histochem. Cytochem. 25:266-274(1977).
RX   PubMed=2903891; DOI=10.1080/09553008814552341;
RA   Peacock J.H., Cassoni A.M., McMillan T.J., Steel G.G.;
RT   "Radiosensitive human tumour cell lines may not be recovery
RT   deficient.";
RL   Int. J. Radiat. Biol. 54:945-953(1988).
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.N.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
RX   PubMed=4027986;
RA   Lin C.-W., Lin J.C., Prout G.R. Jr.;
RT   "Establishment and characterization of four human bladder tumor cell
RT   lines and sublines with different degrees of malignancy.";
RL   Cancer Res. 45:5070-5079(1985).
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
RX   PubMed=6823318; DOI=10.1038/301429a0;
RA   O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.;
RT   "Identity of some human bladder cancer cell lines.";
RL   Nature 301:429-430(1983).
RX   PubMed=6826254; DOI=10.1002/ijc.2910310308;
RA   Paulie S., Hansson Y., Lundblad M.-L., Perlmann P.;
RT   "Lectins as probes for identification of tumor-associated antigens on
RT   urothelial and colonic carcinoma cell lines.";
RL   Int. J. Cancer 31:297-303(1983).
RX   PubMed=7185004; DOI=10.2302/kjm.31.127;
RA   Tachibana M.;
RT   "Studies on cellular adhesiveness in five different culture cell lines
RT   derived from carcinoma of the urinary bladder.";
RL   Keio J. Med. 31:127-148(1982).
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
RX   PubMed=25336970; DOI=10.2147/OTT.S69239;
RA   Yang P.-S., Hsu Y.-C., Lin Y.-H., Hou C.-P., Chen C.-L., Chang P.-L.,
RA   Juang H.-H., Tsui K.-H.;
RT   "The expression sequence tag is an effective method for screening DNA
RT   segments that predict urinary bladder transitional cell carcinoma
RT   prognosis.";
RL   Onco Targets Ther. 7:1777-1781(2014).